reprocyc prrs eu et impranflex susp. inj. (lyoph. + solv.) i.m. flac.
boehringer ingelheim vetmedica gmbh - virus vivant atténué du syndrome dysgénésique et respiratoire porcin (sdrp ou prrsv) - lyophilisat et solvant pour suspension injectable - virus vivant atténué du syndrome dysgénésique et respiratoire porcin (sdrp ou prrsv) - porcine reproductive and respiratory syndrome (prrs) virus - porc
salmoporc susp. inj. (lyoph. + solv.) s.c. flac.
ceva santé animale sa-nv - salmonella typhimurium, vivant, atténué 5 10*8 cfu/dose - 5 10*9 cfu/dose - lyophilisat et solvant pour suspension injectable - salmonella typhimurium - salmonella - porc
salmoporc susp. buv. (lyoph.) flac.
ceva santé animale sa-nv - salmonella typhimurium, vivant, atténué 5 10*8 cfu/dose - 5 10*9 cfu/dose - lyophilisat pour suspension buvable - salmonella typhimurium - salmonella - porc
suvaxyn parvo/e-amphigen émuls. inj. i.m. flac.
zoetis belgium sa-nv - parvovirus porcin ; erysipelothrix rhusiopathiae, inactivé - emulsion injectable - parvovirus porcin; erysipelothrix rhusiopathiae, inactivé - porcine parvovirus + erysipelothrix - porc
unistrain prrs susp. inj. (lyoph. + solv.) i.m./i.derm. flac.
laboratorios hipra - virus vivant atténué du syndrome dysgénésique et respiratoire porcin (sdrp ou prrsv) 10exp3,5 – 10exp5,5 ccid50/dose - lyophilisat et solvant pour suspension injectable - virus vivant atténué du syndrome dysgénésique et respiratoire porcin (sdrp ou prrsv) - porcine reproductive and respiratory syndrome (prrs) virus - porc
fixr salmonella émuls. inj. i.m. flac.
bioveta a.s. - salmonella enterica inactivé ; salmonella enterica inactivé ; salmonella enterica inactivé - emulsion injectable - salmonella typhimurium, inactivé; salmonella derby, inactivé; salmonella infantis, inactivé - salmonella - porc
persovac susp. inj. (lyoph.) i.m. flac.
ceva santé animale sa-nv - virus vivant atténué du syndrome dysgénésique et respiratoire porcin (sdrp ou prrsv) - lyophilisat pour suspension injectable - virus vivant atténué du syndrome dysgénésique et respiratoire porcin (sdrp ou prrsv) - porcine reproductive and respiratory syndrome (prrs) virus - porc
vaccesol solv. pour prép. parent. i.m. flac.
ceva santé animale - eau pour injection - solvant pour préparation parentérale - eau pour injection - porcine reproductive and respiratory syndrome (prrs) virus - porc
fixr parvo lepto émuls. inj. i.m. flac.
kernfarm b.v. - leptospira interrogans australis ; leptospira interrogans pomona ; parvovirus porcin, inactivé ; leptospira kirschneri grippotyphosa ; leptospira interrogans serovar icterohaemorrhagiae, inactivé ; leptospira interrogans sejroe, inactivé ; leptospira interrogans canicola - emulsion injectable - parvovirus porcin; leptospira interrogans australis; leptospira interrogans canicola; leptospira interrogans grippotyphosa; leptospira interrogans icterohaemorrhagiae; leptospira interrogans pomona; leptospira interrogans sejroe - inactivated viral and inactivated bacterial vaccines - porc
mhyosphere pcv id
laboratorios hipra, s.a. - mycoplasma hyopneumoniae, strain 7304 (nexhyon), expressing the capsid protein of porcine circovirus type 2a, inactivated - immunologicals for suidae, inactivated viral and inactivated bacterial vaccines - les cochons - for the active immunisation of pigs:to reduce lung lesions associated with porcine enzootic pneumonia caused by mycoplasma hyopneumoniae. also, to reduce the incidence of these lesions (as observed in field studies). to reduce viraemia, virus load in lungs and lymphoid tissues and the duration of the viraemic period associated with diseases caused by porcine circovirus type 2 (pcv2). efficacy against pcv2 genotypes a, b and d has been demonstrated in field studies. to reduce culling rate and the loss of daily weight gain caused by mycoplasma hyopneumoniae and/or pcv2 related diseases (as observed at 6 months of age in field studies). mycoplasma hyopneumoniae: onset of immunity: 3 weeks after vaccinationduration of immunity: 23 weeks after vaccinationporcine circovirus type 2:onset of immunity: 2 weeks after vaccinationduration of immunity: 22 weeks after vaccinationin addition, a reduction in nasal and faecal shedding and the duration of nasal excretion of pcv2 was demonstrated in animals challenged at 4 weeks and at 22 weeks after vaccination.